U.S. Stem Cell, Inc. filed its 10-K on Mar 31, 2022 for the period ending Dec 31, 2021. In this report its auditor, Russell Bedford Stefanou Mirchandani LLP - RBSM LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | +9,900.00% | +9,900.00% |
2023 | U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2023 | U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt | CI |
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 66.15K | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.75% | 22.2B | |
-16.53% | 21.23B | |
-8.98% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- USRM Stock
- News U.S. Stem Cell, Inc.
- U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt